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BACKGROUND. A Phase II study was initiated to evaluate the effectiveness of an oral
regimen of etoposide and estramustine in patients with early recurrent prostate
carcinoma.
METHODS. Patients with early recurrent prostate carcinoma as indicated by an
increasing prostate specific antigen (PSA) level and without any evidence of met-
astatic disease were treated with oral etoposide 50 mg/m2/day and estramustine 15
mg/kg/day in divided doses for 21 days, followed by a 7-day rest period. Patients
received a maximum of four cycles.
RESULTS. Eighteen patients were entered in this study. The median serum PSA was
3.1 (range, 0.3–30.3) at the time of entry into the trial. Sixteen patients were
assessable for response. Serum PSA declined to undetectable levels in 13 patients
with 2 additional patients meeting the criteria for partial response; the median
duration of response was 8.5 months (range, 1–18 months). Most patients devel-
oped gastrointestinal, cardiac, or hematologic complications. Grade 3 toxicities
included neutropenia (one patient), deep venous thrombosis (three patients), and
chest pain (one patient). One patient developed acute myelogenous leukemia
(French–American–British, acute myelogenous leukemia M5) 23 months after ini-
tiating the chemotherapy.
CONCLUSIONS. The combination of oral etoposide and oral estramustine resulted
in a high rate but only a short duration of response in patients with early recurrent
prostate carcinoma. The regimen was poorly tolerated, and the toxicity was sig-
nificant. This regimen should not be considered standard therapy for the treatment
of early recurrent prostate carcinoma, but further exploration of treatment in this
setting is warranted. Cancer 2001;91:2175– 80. © 2001 American Cancer Society.
KEYWORDS: prostate carcinoma, early recurrent, etoposide, estramustine, chemo-
therapy, leukemia, thrombosis.
Prostate carcinoma is one of the most commonly diagnosed can-cers in American men. In 1999, 179,300 men were expected to
receive a diagnosis of prostate carcinoma in the United States, and
37,000 men were predicted to die of the disease.1 The widespread use
of prostate specific antigen (PSA)– based testing has resulted in a
dramatic increase in the number of men diagnosed with localized
disease.2 Many of these men will undergo either radical prostatec-
tomy or radiotherapy. Unfortunately, approximately 50% of the pa-
tients undergoing prostatectomy3 and approximately 60% of men
treated with radiotherapy will have biochemical recurrence within 10
years.4 Recurrent prostate carcinoma is a significant problem. Some
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of these patients may be offered additional local ther-
apy, and many will be treated with hormonal therapy.5
A significant proportion of these patients will develop
metastatic disease. Unfortunately, the duration of re-
mission with hormonal therapy is limited in patients
with metastatic disease, with androgen failure often
occurring within 18 –24 months of starting therapy.6
Consequently, the survival rates of patients with re-
current disease have not increased over the past 5
decades.7
Prostate carcinoma consists of both androgen-
dependent and androgen-independent clones. Tumor
progression after androgen ablation is due to prolifer-
ation of androgen-independent cells.8 Chemotherapy
has been used to treat patients whose cancers have
become refractory to androgen therapy. Treatment
with an oral regimen of etoposide and estramustine
can achieve a significant response in these patients.9,10
Several additional regimens also have been demon-
strated to have activity in patients with advanced
prostate carcinoma.11 Unfortunately, the median sur-
vival in these Phase III trials of these regimens is only
11–12 months despite the use of chemotherapy.12,13
Patients with advanced prostate carcinoma have a
significant tumor burden, which may limit the effec-
tiveness of the chemotherapy in these trials. There
have been, to our knowledge, no trials reporting treat-
ment of patients with early recurrent prostate carci-
noma with chemotherapy. Here, we report the results
of a trial in patients with minimal disease, as demon-
strated by increasing PSA and without any evidence of
metastatic disease, who were treated with an oral reg-
imen of etoposide and estramustine. The objective of
this Phase II study was to assess the toxicity of this
regimen in this population and the response of mini-
mal disease to therapy as measured by the serum PSA
level.
MATERIALS AND METHODS
Patients were eligible if they had histologically con-
firmed adenocarcinoma of the prostate associated
with elevated PSA that had returned to normal after
primary therapy (, 1.0 ng/mL for prostatectomy pa-
tients or , 4.0 ng/mL for radiation therapy patients)
and had an increasing PSA level that had at least
doubled from their lowest PSA level after the primary
therapy. Patients were required to have a performance
status of 3 or better, with a life expectancy of 12 weeks
or greater, and an adequate bone marrow reserve with
an absolute neutrophil count (ANC) greater than
1500/mm3 and a platelet count greater than 100,000/
mm3. Patients were excluded if computed tomography
(CT) scan or bone scan demonstrated metastatic dis-
ease, or if they had received hormonal therapy for the
treatment of metastatic disease before enrolling in this
trial. All patients gave written informed consent in
accordance with federal, state, and institutional guide-
lines.
Pretreatment evaluations consisted of a history
and physical examination with assessment of perfor-
mance status, and laboratory studies including com-
plete blood count, serum chemistry profile, prothrom-
bin time, PSA level, radionuclide bone scan, CT scan
of the abdomen and pelvis, and chest X-ray. Complete
blood counts were monitored weekly, and the serum
PSA was monitored before each cycle. After 4 cycles of
therapy, serum PSA was measured every 12 weeks.
Patients in this study were treated and followed in
the outpatient clinic. Estramustine was provided by
Pharmacia & Upjohn (Kalamazoo, MI) and etoposide
was supplied by Bristol-Myers Squibb (Nutley, NJ).
Oral estramustine was given at a dose of 10 mg/kg/day
rounded to the nearest multiple of 140 (maximum 2
pills 3 times a day) and oral etoposide 50 mg/m2/day
rounded to the nearest multiple of 50 (maximum 2
pills per day) for 21 days, repeated every 28 days. The
dose of etoposide was decreased to 1 tablet a day
alternating with 1 tablet twice a day for patients with
a body surface area of less than 1.75 m2.
Patients were treated with a maximum of four
cycles of therapy. Retreatment required that the ANC
was greater than 1500/mm3, and the platelet count
was greater than 75,000/mm3 on Day 1 of each cycle.
Dose modification of etoposide was based on Day 21
ANC and platelet count of the preceding cycle for the
next and additional cycles. Etoposide was decreased
to 1 tablet per day alternating with 1 tablet twice a day
for ANC between 1000/mm3 and 1499/mm3 and/or for
platelets between 50,000/mm3 and 74,999/mm3. Eto-
poside was further decreased to 1 tablet per day for
ANC less than 1000/mm3 and/or for platelets less than
50,000/mm3. Etoposide was held for the remainder of
the cycle if patient had an ANC less than 1500/mm3 or
platelet count less than 75,000/mm3 on Days 7 or 14.
Patients were transfused for hemoglobin less than 8.0
g/dL or for symptomatic anemia as evidenced by
shortness of breath or severe fatigue. Patients with
Grades 1 and 2 nausea were treated with antiemetics.
Patients with Grade 3 nausea had their drugs discon-
tinued and were taken off study secondary to toxicity.
After the tenth patient had been enrolled, the subse-
quent patients on this protocol were maintained on 1
mg/day of warfarin for prophylaxis against deep ve-
nous thrombosis.
The study initially was designed to assess re-
sponse as measured by PSA criteria. Complete re-
sponse was defined as a decrease in PSA to undetect-
able levels for at least 4 weeks with maintenance of
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performance status and without the appearance of
new lesions. Partial response was defined as a de-
crease in PSA of greater than or equal to 50% lasting at
least 4 weeks, again with maintenance of performance
status and without the appearance of new lesions.
Disease progression was defined as increase in the
serum PSA level of 100% over baseline or the appear-
ance of new lesions. The protocol used a standard
two-stage Phase II design to limit accrual if extreme
results were demonstrated. Twenty evaluable subjects
were to be enrolled in the first phase, followed by
enrollment of an additional 20 subjects if more than
one but less than six subjects had response. Criteria
for halting enrollment after the first phase also in-
cluded excess toxicity or short duration of response.
This design has a power of 82% to detect a true re-
sponse rate greater than or equal to 25% with a sig-
nificance of 0.0449. Toxicity was graded according to
the revised National Cancer Institute Common Toxic-
ity Criteria.
RESULTS
Between April 1996 and April 1998, 18 patients with
increasing PSA after primary therapy for prostate car-
cinoma were entered onto this trial. The trial was
halted early due to the toxicity of the regimen. Initial
patient characteristics are summarized in Table 1.
Most (nine patients) of the patients had been treated
with both radiation and surgery. Six patients had re-
ceived only radiation treatment, and two patients had
been treated with prostatectomy only. One patient
had been treated with cryosurgery and therefore was
ineligible to participate in the study. Six patients had
received neoadjuvant hormonal therapy with a dura-
tion ranging from 1 to 6 months. All six had received
luteinizing hormone-releasing hormone (LHRH) ago-
nist therapy, with at least four receiving combined
androgen blockade (data not available on one sub-
ject). These patients had a median time to progression
from initiation of hormonal therapy of 12.5 months
(range, 8 –21 months). Overall, the patients enrolled
had a median of 22 months from completion of pri-
mary and/or secondary therapies to biochemical re-
currence of their prostate carcinoma. The median PSA
at the time of entry into the trial was 3.1.
Estramustine and etoposide were administered
orally. Thirteen patients completed all 4 cycles. One
patient completed only three cycles because of severe
agitation. One patient completed two cycles of che-
motherapy and then was removed from the study due
to rapidly progressing disease; he also had a popliteal
deep venous thrombosis. Two additional patients
stopped after two cycles of therapy: one patient devel-
oped deep venous thrombosis, and the other patient
because of tachycardia. One patient had chest pain
while receiving his first cycle of therapy and was taken
off the study.
Most patients developed gastrointestinal symp-
toms (Table 2). Of the 18 patients, 14 patients devel-
oped either Grade 1 or 2 nausea, 4 patients developed
Grade 1 vomiting, and 4 patients had either Grade 1 or
2 diarrhea. Seven patients complained of fatigue, and
four patients had anorexia. Five patients developed
Grade 1 alopecia. Four patients developed deep ve-
nous thrombosis, of which three patients had Grade 3
deep venous thrombosis. The incidence of deep ve-
nous thrombosis was 3 of 10 patients in the group that
was not receiving prophylactic doses of warfarin and 1
of 8 patients in the group that was receiving warfarin.
One patient developed superficial thrombophlebitis;
he was not receiving warfarin. Two patients had major
cardiac toxicity with one patient developing chest pain
and the other patient developing arrhythmia. Four
patients had neutropenia, including one patient who
developed Grade 3 toxicity. Two patients had Grade 2
anemia. Other toxicities included bronchitis (three pa-
tients), edema (two patients), gynecomastia (two pa-
tients), depression (two patients), anxiety (two patients),
and rash (one patient).
One patient, who had received a total oral etopo-



















Neoadjuvant hormonal therapy 6
Interval (mos) between completion of primary
therapy and increase in the serum PSA
Median 22
Range 3–57
PSA at the time of chemotherapy
Median 3.1
Range 0.3–30.3
PSA: prostate specific antigen.
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nous leukemia, French–American–British (FAB) clas-
sification system M5, 23 months after initiation of
treatment with etoposide and estramustine. He was
noted to have a mildly elevated leukocyte count with
circulating early leukocyte precursors. Bone marrow
aspirate showed acute myelogenous leukemia, mono-
cytoid form. Bone marrow cytogenetics showed that
22 of 26 cells had translocation between the long arm
of chromosome 11 and a short arm of chromosome 19
(46, XY, t[11;19][q23;p13]). Two of 26 cells had, in
addition to the t(11;19) translocation, a trisomy 8 and
an abnormal chromosome consisting of the long arms
of chromosome 10 and 15. He underwent induction
with cytosine arabinoside and idarubicin. Repeat bone
marrow cytogenetics showed that the patient had per-
sistent t(11;19) translocation, indicating the presence
of residual leukemia. He subsequently received con-
solidation therapy with two cycles of high dose cytar-
abine and underwent a matched-unrelated donor al-
logeneic bone marrow transplant. At more than 450
days after transplant, he was without evidence of re-
currence of his acute myelogenous leukemia (AML).
Sixteen of the 18 patients were assessable for re-
sponse (Table 3). One patient was excluded even
though he had completed all four cycles because he
previously had been treated with cryosurgery and was
ineligible to participate per protocol. A second patient
was not evaluable because he was placed on total
androgen blockade after developing a deep vein
thrombosis during his second cycle of therapy. Both of
these patients are included in assessing the toxicity of
this regimen. Thirteen patients had a decline in their
serum PSA to undetectable levels. The duration of the
serum PSA nadir was a median of 6 months, ranging
from 1 to 18 months. Two of the remaining three
evaluable patients met the criteria for partial response,
for an overall response rate of 94% (15 of 16). Median
duration of response was 8.5 months with a range of 1
to 18 months. Patients were treated with hormonal
therapy within a median of 3 months after failing
chemotherapy. One patient, who completed only two-
thirds of a cycle of protocol therapy, was not treated
with hormonal therapy for almost 2 years. His serum
PSA decreased to a nadir of 0.3 2 months after with-
drawing from the trial, with subsequent slow increase
over the following 21 months to reach a high of 6.6 at
the time of initiation of hormonal therapy. These sub-
sequent therapies consisted of bicalutamide and fin-
asteride (9 patients), total androgen blockade (4 pa-
tients), and LHRH agonist monotherapy (3 patients).
One patient took finasteride for 2 months and then was
placed on total androgen blockade. All but one of the
patients responded to initiation of hormonal therapy
with a prompt decrease in PSA. The nonresponding pa-
tient was the one who developed rapidly progressive
disease while on protocol therapy. He had no response
to total androgen blockade and died of progressive dis-
ease 7 months after entry onto the protocol.
DISCUSSION
There are increasing numbers of patients with pros-
tate carcinoma who at the time of recurrence have
only minimal disease. The optimal treatment strategy
for these patients is not known. In this trial, we treated
this select group of patients with an oral regimen of
etoposide and estramustine.
Sixteen patients were assessable for response. Be-
cause the patients did not have detectable disease by
bone scan or computed tomography, the response to
therapy was assessed with serum PSA level. Fifteen of




Grade (no. of patients)
Percentage1 2 3 4




Neutropenia 2 1 1 22
Venous thrombosis 1 3 22
Vomiting 4 22
Diarrhea 2 2 22
Bronchitis 1 2 17
Anemia 2 11










No. of cycles 62 (1–4)
Response
Undetectable PSA (CR) 13
PR 3
Total (CR/PR) 16/17
Median duration of CR 6 (1–18)
Median duration of response 8.5 (1–18)
No. receiving hormonal therapy after treatment failure 15
PSA: prostate specific antigen; CR: complete response; PR: partial response.
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complete response in 13 patients. The median dura-
tion of response was 8.5 months, with a maximum
duration of response of 18 months. This response is
possibly due to the hormonal effect of estramustine,
which has been reported to induce castrate levels of
serum testosterone.14 Serum testosterone levels were
not measured as part of this study. The relative con-
tributions of this hormonal effect to the overall effi-
cacy of the therapy therefore is not clear. In an earlier
trial in patients with hormone refractory prostate car-
cinoma using the same dose of etoposide and estra-
mustine as in this study, the serum PSA declined by at
least 50% from baseline in 39% of the patients.15 Thus,
by treating patients with minimal disease, we were
able to achieve a higher response rate, as would be
expected in patients with androgen-dependent dis-
ease. Unfortunately, all patients eventually recurred,
and nearly all were treated subsequently with hor-
monal therapy.
The toxicity of this regimen was substantial and
resulted in early termination of the study. Grade 3 tox-
icities included neutropenia, venous thrombosis, angina,
and dysrhythmia. Five of 18 patients failed to complete
all 4 cycles. Chest pain, dysrhythmia, and venous throm-
boses were the main reasons for discontinuation of the
therapy. Most of these symptoms were in patients who
were not receiving prophylactic doses of warfarin. Four
patients developed deep venous thrombosis, only one of
whom was receiving 1 mg/day of warfarin. The two
patients who withdrew from the study because of deep
venous thrombosis were not receiving warfarin. In the
prior report with 62 hormone refractory disease patients
using the same chemotherapy dosages, only Grade 1
venous thrombosis was observed, with no patient stop-
ping therapy as a result, despite no prophylaxis for
thrombosis.10 Furthermore, the patients in that report
were not maintained on prophylactic doses of couma-
din. Fourteen of the 18 patients on this study reported
nausea, most being Grade 1 nausea. No patients with-
drew from the study secondary to nausea. In the previ-
ous study involving patients with more advanced dis-
ease, three (5%) patients quit secondary to Grade 3
nausea.10 The discrepancy in toxicity between this study
and the earlier study may be an artifact of the low num-
ber of patients enrolled or may be due to factors associ-
ated with the stage of disease.
One of the patients developed AML, FAB M5 sub-
type, 23 months after initiation of treatment with oral
etoposide and estramustine. Etoposide is well known
to increase the risk of leukemia, particularly acute
myelomonocytic (FAB M4) and acute monocytic (FAB
M5) leukemias.16 The median latency period between
treatment with etoposide and the development of leu-
kemia is 28 months (range, 11– 84 months). The risk of
developing secondary leukemia is 2– 4%, with risk in-
creased in those patients who have received higher
cumulative dose (.2000 mg/m2 parenterally) and in
those patients receiving the etoposide on a weekly or
biweekly schedule. The cumulative dose of oral eto-
poside received by patients in this trial who complete
all 4 cycles is 4200 mg/m2. The bioavailability of oral
etoposide is approximately 50%, although the range
varies widely from 25% to 75%.16,17 Thus, the equiva-
lent parenteral dose received by patients in our trial
ranged from 1050 to 3150 mg/m2. Approximately 1%
(2 patients) of the patients with recurrent prostate
carcinoma who have been enrolled in trials involving
treatment with etoposide have developed AML at our
institution. Patients with secondary leukemia from
etoposide characteristically have translocations in-
volving the short arm of chromosome 9 or the long
arm of chromosome 11. Our patient had t(11;19)(q23;
p13) translocation, and because durable remission
with standard therapy was unlikely, he underwent al-
logeneic bone marrow transplantation.
We treated a small, but heterogeneous group of
patients with chemotherapy. The initial Gleason
scores ranged from 5 to 9, and the interval between
primary therapy and an increase in the serum PSA
level ranged from 3 to 51 months. Recently, the natu-
ral history of prostate carcinoma in patients who have
elevated PSA levels as the only manifestation of recur-
rence, similar to patients in this trial, has been de-
scribed.18 The median time to metastasis was 5 years
from the time of PSA elevation, and only 34% of the
patients developed metastasis at 5 years. The risk of
developing metastatic disease after biochemical re-
currence correlated with the time to biochemical pro-
gression, the Gleason score, and the PSA doubling
time. Using this information, it is possible to predict
which patients are likely to progress to have metastatic
disease and which patients will have indolent disease.
The patients in our trial would have been predicted to
have a high likelihood of developing metastatic dis-
ease over the next 5 years. Even though watchful wait-
ing may be a reasonable option for those patients
predicted to have indolent disease, it would not have
been the best course of action for most of the patients
enrolled in our trial.
Besides watchful waiting, patients with biochem-
ical recurrence have been treated with hormonal ther-
apy. There has been significant controversy surround-
ing the optimal time to initiate hormonal treatment. A
large randomized study conducted by the Veteran’s
Administration Co-operative Urological Research
Group found no survival advantage with early treat-
ment.19 A more recent study reported a trend toward
increased survival with early therapy.20 There were
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significantly fewer spinal cord compressions and
pathologic fractures in the group treated with early
hormonal therapy on this study. A recently reported
prospective Phase III trial showed that there was im-
proved survival for patients with lymph node positive
disease treated with early hormonal therapy com-
pared with delayed hormonal therapy.21
In summary, treatment with an oral regimen of
etoposide and estramustine resulted in a high re-
sponse rate but was poorly tolerated in this group of
men with biochemical recurrence of their prostate
carcinoma. Toxicity with this regimen was substantial,
and the duration of response was short. We therefore
would not recommend that this regimen be incorpo-
rated into the standard treatment of biochemically
recurrent hormone-responsive prostate carcinoma.
Despite this somewhat discouraging result, further ex-
ploration of therapy in this setting is clearly warranted.
The median survival for patients with hormone refrac-
tory prostate carcinoma remains approximately 1 year,
pointing to the urgent need to find treatments for
patients with recurring prostate carcinoma before
their progression to androgen-independent disease.
The development of new regimens and novel ap-
proaches and a better understanding of the biology of
prostate carcinoma and the further development of
prognostic indicators that will allow the identification
of those patients at risk for death due to prostate
carcinoma will allow us to further evaluate the con-
cept of treatment in the setting of minimal disease.
Treatment in this clinical setting will require a careful
assessment of the potential benefits and toxicities of
therapy, particularly in light of the asymptomatic sta-
tus of most of this population. The need to minimize
toxicity must be balanced by the risk that several of
these patients will go on to develop symptomatic met-
astatic disease that may prove lethal. Regimens cur-
rently under development hopefully will have fewer
toxicities and greater efficacy allowing the promise of
early therapy for metastatic disease to be realized.
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